Nanjing KMK Pharmaceutical

Nanjing KMK Pharmaceutical is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on selective kinase inhibitors, with a significant emphasis on Tyrosine kinase 2 (TYK2) and Janus kinase (JAK) pathways to treat autoimmune and inflammatory diseases. Its lead programs, such as KMK-181, are designed to offer high selectivity to minimize off-target effects associated with traditional pan-JAK inhibitors. Nanjing KMK Pharmaceutical aims to address significant unmet medical needs in dermatology, gastroenterology, and rheumatology through its internal R&D engine.